Titan Pharmaceuticals (DB:TN70) - Stock Price, News & Analysis

TN70 Stock Overview

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.

About the company

TN70 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 6.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (€5M)

Makes less than USD$1m in revenue ($184K)

Has less than 1 year of cash runway

Titan Pharmaceuticals, Inc. Competitors

Biofrontera

XTRA:B8F

€21.8m

SynBiotic

DUSE:SBX

€43.1m

Apontis Pharma

XTRA:APPH

€73.0m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Titan Pharmaceuticals
Historical stock prices
Current Share Price	US$5.92
52 Week High	US$15.00
52 Week Low	US$4.40
Beta	1.35
1 Month Change	0%
3 Month Change	-20.90%
1 Year Change	-59.75%
3 Year Change	-86.85%
5 Year Change	-99.23%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	TN70	DE Pharmaceuticals	DE Market
7D	0%	2.6%	2.5%
1Y	-59.7%	-22.6%	6.0%

Return vs Industry: TN70 underperformed the German Pharmaceuticals industry which returned -31.5% over the past year.

Return vs Market: TN70 underperformed the German Market which returned 4.1% over the past year.

Price Volatility

Is TN70's price volatile compared to industry and market?
TN70 volatility
TN70 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: TN70's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine TN70's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	4	David Lazar	www.titanpharm.com

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.

Titan Pharmaceuticals, Inc. Fundamentals Summary

How do Titan Pharmaceuticals's earnings and revenue compare to its market cap?
TN70 fundamental statistics
Market cap	€4.77m
Earnings (TTM)	-€5.13m
Revenue (TTM)	€169.57k

28.1x

P/S Ratio

-0.9x

P/E Ratio

Is TN70 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TN70 income statement (TTM)
Revenue	US$184.00k
Cost of Revenue	US$0
Gross Profit	US$184.00k
Other Expenses	US$5.75m
Earnings	-US$5.57m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-7.37
Gross Margin	100.00%
Net Profit Margin	-3,026.63%
Debt/Equity Ratio	7.5%

How did TN70 perform over the long term?

See historical performance and comparison

TN70 Stock Overview

Rewards

Risk Analysis

Titan Pharmaceuticals, Inc. Competitors

XTRA:B8F

€21.8m

DUSE:SBX

€43.1m

XTRA:APPH

€73.0m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

New major risk - Financial position

Recent updates

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

New major risk - Financial position

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

New minor risk - Share price stability

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought €52k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Insider recently bought €1.6m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought €324k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought €146k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: €2.48

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

New 90-day low - €0.22

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020